Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

404 results about "Cisplatin" patented technology

Cisplatin is used to treat various types of cancer.

KRASG12D-targeted substituted quinolinone compound and application thereof

The invention relates to the field of medicinal chemistry, in particular to a substituted quinolinone compound targeting KRASG12D and application of the substituted quinolinone compound. Pharmacological tests prove that the affinity effect of the synthesized compound on a KRASG12D mutant is superior to that of a lead compound KAL-21404358. The compounds WY1-014 and WY1-062 have ideal inhibition effects on cells of human lung cancer (A549), human melanoma (A375) and human colon cancer (LOVO). The compound WY1-062 has excellent anti-tumor activity, and the activity of the compound WY1-062 is superior to that of cis-platinum.
Owner:SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCI

Traditional Chinese medicine composition, preparation method thereof and application of traditional Chinese medicine composition in preparation of medicine for preventing and treating ovarian reserve function decline

PendingCN121081564APowder deliveryLyophilised deliverySalvia miltiorrhizaFollicular antrum
The invention discloses a traditional Chinese medicine composition, a preparation method thereof and an application of the traditional Chinese medicine composition in preparation of a medicine for preventing and treating ovarian reserve hypofunction, and belongs to the technical field of traditional Chinese medicines. The composition is prepared from the following raw materials in parts by weight: 10 to 15 parts of radix paeoniae alba, 6 to 10 parts of radix bupleuri, 10 to 15 parts of radix rehmanniae preparata, 15 to 30 parts of stir-fried rhizoma dioscoreae, 12 to 20 parts of semen cuscutae, 10 to 12 parts of radix angelicae sinensis, 10 to 15 parts of poria cocos, 12 to 25 parts of fructus ligustri lucidi, 10 to 15 parts of radix salviae miltiorrhizae, 10 to 15 parts of fructus corni and 10 to 15 parts of radix morindae officinalis. The traditional Chinese medicine composition can obviously reduce the level of follicle-stimulating hormone (FSH) of cis-platinum model mice, increase estradiol (E2), increase the number of follicles at all levels, especially the number of primordial follicles, and reduce the number of atresia follicles; the ovarian function of naturally aged mice can be improved, FSH (follicle stimulating hormone) is reduced, anti-mullerian hormone (AMH) and E2 are increased, and the quantity of follicles at all levels, especially the quantity of corpus luteum, primordial follicles and anterior sinus follicles, is increased; therefore, the composition disclosed by the invention has an obvious protection effect on the hypoovarian reserve function.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Ceacam5 ADC-Anti-PD1 / PD-l1 combination therapy

Provided are methods for combination treatment of a cancer using an antibody-drug conjugate (ADC) targeting CEACAM5 and an anti-PD-1 antibody or anti-PD-L1 antibody, optionally together with a platinum-containing agent such as cisplatin or carboplatin with or without pemetrexed. In certain embodiments the ADC is tusamitamab ravtansine. In certain embodiments the anti-PD-1 antibody is pembrolizumab. In certain embodiments, the cancer is nonsquamous non-small cell lung cancer (NSQ NSCLC). In certain embodiments, the cancer is advanced or metastatic NSQ NSCLC.
Owner:SANOFI SA(FR)

Copper complex with anticancer activity and preparation method and application thereof

The invention belongs to the field of anti-cancer metal complexes, and particularly relates to a copper complex with anti-cancer activity and a preparation method and application thereof. Cu (OAc) 2H2O and coumarin-3-formyl-(2-aminomethylpyridine) are respectively dissolved in a solvent, the two solutions are mixed and stirred at room temperature to react for a period of time, the reaction solution is filtered, the filtrate is sealed and naturally volatilized at room temperature for 3-7 days, the complex can be obtained, the IC50 value of the complex to Hela cervical cancer cells is 0.8964 + / -0.09 mu M, and the IC50 value of the complex to Hela cervical cancer cells is 0.8964 + / -0.09 mu M. According to the present invention, the inhibition effect of the complex on HeLa cervical cancer cells is 3.38 times of the inhibition effect of cis-platinum, the toxicity of the complex on normal cells but HUVEC is very small, IC50 is greater than 100 [mu] M, and the complex has a high selectivity coefficient SI (SI = normal cell IC50 / cancer cell IC50), and the selectivity coefficient SI is greater than 111 and is 584 times of the selectivity coefficient of cis-platinum (SI = 0.19). The complex has the capability of inducing apoptosis of cancer cells and has concentration dependence. Meanwhile, the complex can retard cancer cells and an S phase so as to inhibit cell proliferation, and can generate an intercalation effect with HS-DNA (High-Speed Deoxyribose Nucleic Acid).
Owner:NANJING FORESTRY UNIV

Application of Ptprj agonist GJ103 in preparation of medicine for treating cisplatin-induced acute kidney injury

The invention belongs to the field of biological medicines, and particularly discloses application of a Ptprj agonist GJ103 in preparation of a medicine for treating acute kidney injury (AKI) induced by cisplatin. In-vivo and in-vitro experiments prove that the GJ103, by activating Ptprj, can significantly down-regulate expression of pro-apoptotic protein Bax and Cleved Caspase-3, up-regulate anti-apoptotic protein Bcl2 and reduce infiltration of inflammatory factors TNF-alpha and IL-6, so that apoptosis and inflammatory response of renal tubular epithelial cells are relieved. In in-vivo experiments, GJ103 (20-40mg / kg / day) can reduce serum creatinine and urea nitrogen levels of cis-platinum model mice and improve pathological injuries such as renal tubule dilatation; in in-vitro experiments, 20-40 [mu] M of GJ103 can inhibit apoptosis of renal tubular epithelial cells and reduce expression of renal injury markers NGAL and Kim-1. The pharmaceutical composition contains GJ103 and a pharmaceutical carrier, the preparation form can be a 4mg / mL injection (the purity is greater than or equal to 99.46%) or an oral preparation, and a new strategy is provided for clinical treatment of cisplatin renal toxicity.
Owner:NANJING CHILDRENS HOSPITAL

Primary multidrug resistant human distal bile duct cancer cell line CBC3T-6 Homo sapiens and application thereof

PendingCN119265128AStable traitsshort doubling timeCompound screeningCompounds screening/testingExtrahepatic CholangiocarcinomaBasic research
The invention belongs to the technical field of microbial medicine, and provides a primary multidrug resistance human far-end bile duct cancer cell line CBC3T-6 Homo sapiens and application thereof.The human far-end bile duct cancer cell line CBC3T-6 Homo sapiens is separated from differentiated adenocarcinoma in a far-end bile duct, the human far-end bile duct cancer cell line CBC3T-6 Homo sapiens is already subcultured to 50 generations at present, the long-term in-vitro culture character is stable, and on the premise that the biological characteristics of bile duct cancer are reserved, the human far-end bile duct cancer cell line CBC3T-6 Homo sapiens can be used for preparing the primary multidrug resistance human far-end bile duct cancer cell line CBC3T-6 Homo sapiens. The compound has the characteristics of short multiplication time, high mouse subcutaneous tumor formation rate and the like, and has different degrees of drug resistance to gemcitabine, 5-fluorouracil, oxaliplatin and cis-platinum in first-line anti-cancer drugs for bile duct cancer. The method not only enriches an extrahepatic bile duct cancer cell bank, provides a new cell model for basic research and clinical drug research and development of bile duct cancer, but also provides powerful scientific research data for research developed based on the genetic background of Chinese population. Therefore, the primary multidrug resistant cell line has higher scientific research and clinical application values.
Owner:THE FIRST HOSPITAL OF LANZHOU UNIV

Application of chlorbenazolic acid and pharmaceutically acceptable salt thereof in preventing, relieving or treating diseases related to HIF-2alpha

The invention belongs to the technical field of biological medicine, and particularly relates to application of chlorbuconazole or salt thereof in preventing, relieving or treating diseases related to HIF-2alpha. In-vitro experiments prove that the chlorbuconazole enhances the transcriptional activity of HIF-2alpha so as to promote the expression of downstream genes regulated and controlled by the HIF-2alpha; it is proved that chlorburazol has the effects of increasing erythropoiesis and relieving renal injury on an aristolochic acid-induced zebra fish chronic kidney disease model, a cisplatin-caused acute kidney injury and renal anemia model and a unilateral ureteral obstruction model. Meanwhile, the traditional Chinese medicine composition belongs to new use of old medicines, so that the medicine research and development cost and the treatment cost are saved, and the traditional Chinese medicine composition has obvious economic benefits and clinical application values.
Owner:HUAYAO JIYUAN (SHENZHEN) PHARMACEUTICAL CO LTD

Interpretable deep learning predicts chemoresistance

PCT designated stage expiredWO2025155628A1Medical data miningDrug and medicationsTyrosineTumor cells
An ensemble of predictive models that elucidate how cancer mutations impact the response to common replication stress-inducing (RSi) agents. The models implement recent advances in deep learning to facilitate multi-drug prediction and mechanistic interpretation. Initial studies in tumor cells identify 41 molecular assemblies that integrate alterations in hundreds of genes for accurate drug response prediction. These cover roles in transcription, repair, cell-cycle checkpoints, and growth signaling, of which 30 are shown by loss-of-function genetic screens to regulate drug sensitivity or replication restart. The model translates to cisplatin-treated cervical cancer patients, highlighting an RTK (receptor tyrosine kinase)-JAK-STAT assembly governing resistance. This invention defines a compendium of mechanisms by which mutations affect therapeutic responses, with implications for precision medicine.
Owner:RGT UNIV OF CALIFORNIA

Lung cancer cell membrane bionic targeting precious metal-based PLGA nano drug-loaded particle as well as preparation method and application thereof

ActiveCN119185578Areduce early releaseReduce non-specific toxicityInorganic active ingredientsEnergy modified materialsCancer cellCell membrane
The invention discloses a lung cancer cell membrane bionic targeting precious metal-based PLGA nano drug-loaded particle, which comprises a drug-loaded inner core and a lung cancer cell membrane coating the inner core, the drug-loaded inner core structure sequentially comprises an inner core layer and an intermediate core layer, the inner core layer is a chemotherapeutic drug cisplatin, the intermediate core layer is PLGA with good biocompatibility, and the drug-loaded inner core structure sequentially comprises an outer core layer and an inner core layer. The outer surface of the PLGA is modified with noble metal, and the noble metal is one or two of gold, ruthenium and platinum. The invention also discloses a preparation method of the lung cancer cell membrane bionic targeting noble metal-based PLGA nano drug-loaded particle. According to the drug-loaded nanoparticle and the preparation method thereof, tumor cells can be effectively targeted, heat is generated under near-infrared irradiation, the drug cis-platinum loaded in the PLGA NPs can be exposed and released from the inside, and the effect of chemotherapy-photo-thermal synergistic treatment is achieved.
Owner:张冀松

Application of therapeutic target to preparation of medicine for resisting cancer cell cis-platinum resistance

The invention discloses application of a therapeutic target to preparation of a drug for resisting cancer cell cis-platinum resistance. The therapeutic target is NPR1; the NPR1 is used for inhibiting mitochondrial autophagy-dependent ferroptosis by inhibiting the ubiquitination degradation level of PARL. The invention discloses a therapeutic target NPR1 and an NPR1-MARCH8-PARL axis, expression of PARL can be down-regulated by blocking or inhibiting the NPR1 or NPR1-MARCH8-PARL axis, and a mitochondrial autophagy-dependent ferroptosis process can be recovered, so that drug resistance of gastric cancer cells is inhibited, and a new method is further provided for preparing drugs for resisting cisplatin drug resistance of the gastric cancer cells.
Owner:THE FIRST AFFILIATED HOSPITAL OF WANNAN MEDICAL COLLEGE (YIJISHAN HOSPITAL OF WANNAN MEDICAL COLLEGE)

Black ginseng extract for relieving acute kidney injury caused by chemotherapy as well as preparation method and application of black ginseng extract

The invention belongs to the technical field of medicines, and particularly relates to a preparation method of a scrophularia ningpoensis extract for relieving chemotherapy-induced acute kidney injury and application of the scrophularia ningpoensis extract in preparation of a product for relieving chemotherapy-induced acute kidney injury. The preparation method comprises the following steps: putting fresh ginseng into a high-temperature and high-pressure sterilization pot, steaming at 110-120 DEG C for 1-3 hours, taking out, cooling to room temperature, and repeating the steaming cooling process for 2-5 times; and crushing the treated ginseng materials, adding a mixed strain of saccharomyces cerevisiae and lactobacillus plantarum in a mass ratio of 1: 1, fermenting for 24-72 hours, filtering fermentation liquor, and drying filter residues to obtain the black ginseng extract. The cisplatin-induced acute kidney injury is prevented and / or treated by improving oxidative stress and mitochondrial functional activity, reducing the content of lipid peroxide, inhibiting expression of inflammatory factors TNF alpha, IL1beta and COX2 and remarkably reducing the cell apoptosis rate and the level of inflammatory factors related to endoplasmic reticulum stress.
Owner:JILIN UNIVERSITY

Drug combined preparation of chlorbuconazole and pharmaceutically acceptable salt thereof and proline hydroxylase inhibitor

The invention belongs to the technical field of biological medicines, and particularly relates to a combined preparation of chlorbuconazole or pharmaceutically acceptable salt thereof and a proline hydroxylase inhibitor medicine. The combined use of the chlorbuconazole and the proline hydroxylase inhibitor drug can activate the expression of the downstream target gene of the HIF-2alpha, and a synergistic effect is shown. In a cisplatin-induced renal anemia model, the chlorprazole acid can enhance the effect of the proline hydroxylase inhibitor on treating renal anemia.
Owner:HUAYAO JIYUAN (SHENZHEN) PHARMACEUTICAL CO LTD

Cisplatin particles and uses thereof

Compositions of particles having at least 95% by weight of cisplatin and a specific surface area (SSA) of at least 3.5 m2 / g. methods for their use. and methods for their production are provided.
Owner:CRITITECH INC

Application of Lianjing black-bone chicken Baifeng pill in preparation of medicine for treating premature ovarian failure

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a new application of a Homai black-bone chicken Baifeng pill in preparation of a medicine for treating premature ovarian failure. According to the invention, a chemotherapy-induced premature ovarian failure rat model is established by intraperitoneal injection of cis-platinum, an immune premature ovarian failure mouse model is established by subcutaneous multi-point injection of mouse zona pellucida polypeptide 3 (pZP3), and the influence of Jianjing black-bone chicken Baifeng pills on animal estrus cycles, visceral organ coefficients, serum sex hormone levels and ovarian histopathologic changes of the two models is observed. The treatment effect of the Hoojing black-bone chicken Baifeng pill on the premature ovarian failure is verified and defined, the new clinical application of the medicine is expanded, and a new treatment medicine and means are provided for treating the premature ovarian failure, so that a technical support is provided for clinical precise medication.
Owner:BEIJING TONGRENTANG CO LTD

Perigord truffle exosome for improving renal injury and preparation method of perigord truffle exosome

The invention discloses a perigord truffle exosome for improving renal injury and a preparation method of the perigord truffle exosome, and belongs to the technical field of biological medicines. According to the preparation method of the perigord truffle exosome, the perigord truffle exosome is extracted from perigord truffle through a high-speed centrifugation method. By verifying the effect of the perigord truffle exosome in preventing and treating the cisplatin-induced acute kidney injury, experimental data support is provided for clinical medication for preventing and treating the cisplatin-induced acute kidney injury, and meanwhile the application range of perigord truffle and the perigord truffle exosome is widened. The perigord truffle exosome provided by the invention can reduce acute kidney injury caused by cisplatin, thereby achieving the purposes of protecting chemotherapy patients and accepting cisplatin treatment.
Owner:JIANGNAN UNIV +1

Prediction marker eccDNAcircATP6V0A1 for cis-platinum drug resistance of hypopharyngeal cancer and application of prediction marker eccDNAcircATP6V0A1

The invention discloses an eccDNAcircATP6V0A1 serving as a predictive marker of cis-platinum drug resistance of hypopharyngeal cancer and an application of the eccDNAcircATP6V0A1. The nucleotide sequence of the predictive marker eccDNA is as shown in SEQ ID NO. 3. According to the invention, a hypopharyngeal carcinoma cisplatin drug-resistant cell line model FaDu / DDP is cultured for the first time, meanwhile, a differential eccDNA expression profile and a circRNA expression profile in hypopharyngeal carcinoma cells FaDu and hypopharyngeal carcinoma cisplatin drug-resistant cells FaDu / DDP are disclosed and analyzed in a combined manner, and the eccDNA circATP6V0A1 is further screened and verified as a predictive marker of hypopharyngeal carcinoma cisplatin drug resistance through combined analysis. And a new treatment strategy diagnosis and treatment thought is provided for cis-platinum chemotherapy of hypopharyngeal carcinoma patients clinically.
Owner:THE THIRD XIANGYA HOSPITAL OF CENT SOUTH UNIV

Application of selenium-containing preparation in medicine for antagonizing NK cell injury caused by chemotherapy and medicine

The invention provides an application of a selenium-containing preparation in a drug for antagonizing NK cell injury caused by chemotherapy and a drug for antagonizing cisplatin or adriamycin induced NK cell injury. At present, common cancer treatment methods include operative treatment, chemotherapy, radiotherapy and immunotherapy, and chemotherapy is still a main treatment means for most advanced malignant tumors. Meanwhile, chemotherapy has an inhibition effect on an immune system, which is mainly manifested in that the immune system of a patient is damaged and T cells and NK cells are reduced due to direct killing of chemotherapy drugs on immune cells, so that the normal physiological function of the immune system is influenced, tumor cells can be induced to generate immune tolerance, and the metastasis of the tumor cells is accelerated. The selenium-containing preparation is applied to antagonism of induced damage of cis-platinum or adriamycin to NK cells, damage of cis-platinum or adriamycin to NK cells can be antagonized, and effectiveness of chemotherapy and immunotherapy is improved.
Owner:JINAN UNIVERSITY

Application of pharmaceutical composition targeting Beclin 1 in preparation of antitumor drugs

The invention discloses an application of a Beclin 1 targeting pharmaceutical composition in preparation of antitumor drugs. The pharmaceutical composition comprises stapled peptides targeting Beclin 1 and platinum chemotherapeutic drugs. The treatment effect of the pharmaceutical composition on ovarian cancer is verified through an in-vitro cell model and an in-vivo mouse model, the combined use of the stapled peptide i7-01s-31 targeting Beclin 1 and cis-platinum can further amplify the anti-tumor effect of the stapled peptide i7-01s-31 and cis-platinum, the synergistic interaction effect is achieved, and the pharmaceutical composition can be used for treating ovarian cancer. The problem that drug resistance is easily generated due to single use of cis-platinum in actual clinical application is avoided; meanwhile, the dosage of chemotherapeutic drugs can be reduced through drug combination, so that the treatment safety is improved, and the toxicity is reduced.
Owner:THE HONG KONG POLYTECHNIC UNIV SHENZHEN RES INST

Pharmaceutical composition for treating osteosarcoma and application thereof

The invention discloses a pharmaceutical composition for treating osteosarcoma and application of the pharmaceutical composition, and particularly belongs to the field of biological medicine. The pharmaceutical composition comprises cis-platinum and daidzin, the daidzin provided by the invention is combined with beta-catenin protein, so that the protein stability of the beta-catenin protein is reduced, and a Wnt signal channel is further inhibited, so that the activity of osteosarcoma cells is inhibited, cell apoptosis is induced, and pulmonary metastasis is inhibited; the pharmaceutical composition of cis-platinum and daidzin provided by the invention has a synergistic effect, the sensitivity of cells to cis-platinum is remarkably improved, and the daidzin and cis-platinum combined medication has a remarkable inhibition effect on the activity and migration invasion ability of osteosarcoma cells.
Owner:THE THIRD AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY (GUANGZHOU SEVERE MATERNAL TREATMENT CENTER GUANGZHOU ROUJI HOSPITAL)

Nano-drug, preparation method and application thereof, and chemotherapy-photodynamic combined diagnosis and treatment reagent

The invention belongs to the technical field of anti-cancer drugs, and particularly relates to a nano-drug, a preparation method and application thereof, and a chemotherapy-photodynamic combined diagnosis and treatment reagent. The nano-drug provided by the invention comprises a vitamin E polyethylene glycol succinate nano-micelle, and a lauric acid modified tetravalent platinum prodrug, a hydrophobic photosensitizer and an emulsifier which are coated in the vitamin E polyethylene glycol succinate nano-micelle. According to the invention, co-transportation of the cis-platinum prodrug and the photosensitizer can be realized; after the nano-drug provided by the invention is passively transported into tumor cells in a targeted manner through an EPR effect, the hydrophobic photosensitizer can increase the generation of singlet oxygen under the irradiation of red light and cooperates with a chemotherapy drug (tetravalent platinum) to act together, chemotherapy and photodynamic therapy are combined, drug resistance can be overcome, and a good treatment effect is achieved; in the treatment process, the dosage of chemotherapeutic drugs is remarkably reduced, and side effects are greatly reduced.
Owner:SHENZHEN UNIV

Bicyclic peptidyl inhibitors

The present disclosure provides a large combinatorial library of cell-permeable bicyclic peptides. The bicyclic peptides described herein include the first ring consisted of randomized peptide sequences for potential binding to a target of interest while the second ring featured a family of different cell-penetrating motifs, for both cell penetration and target binding. The library was screened against the IκB kinase α / β (IKKα / β)-binding domain of NF-κB essential modulator (NEMO), resulting in the discovery of several cell-permeable bicyclic peptides which inhibited the NEMO-IKKβ interaction, thereby selectively inhibiting canonical NF-κB signaling in mammalian cells and the proliferation of cisplatin-resistant ovarian cancer cells.
Owner:OHIO STATE INNOVATION FOUND

A polysaccharide with protective effects against kidney damage

The present invention provides a polysaccharide that has a protective effect on kidney damage. The polysaccharide of the present invention is obtained from the receptacle of Podocarpus carylus or Podocarpus brevifolia, plants of the Podocarpaceae family, after ultrasonic extraction, distilled water reheating extraction, reduced pressure concentration, ethanol precipitation, and freeze-drying. According to content determination, the mass percentage of the polysaccharide of the present invention is greater than or equal to 50% in terms of glucose. The polysaccharide is composed of 7 monosaccharides, including mannose, rhamnose, glucose, galactose, xylose, arabinose and L-fucose. In vivo experiments on mice have confirmed that the polysaccharide of the present invention has a good protective effect on kidney damage caused by cisplatin. The polysaccharide of the present invention can be used to prepare medicines with a protective effect on kidney damage.
Owner:GUANGXI MEDICAL UNIVERSITY

Iron complex, preparation method and application thereof

The application belongs to the technical field of antitumor drugs, and discloses an iron complex as well as a preparation method and application thereof.The preparation steps of the iron complex are as follows: 1, reacting 2-hydrazinylbenzothiazole, a ketone compound and a solvent to obtain a ligand; and 2, reacting the ligand, ferric chloride and a solvent, and then cooling and crystallizing to obtain the iron complex.The obtained iron complex can effectively induce cancer cell ferroptosis, can effectively inhibit the growth of breast cancer, lung cancer, liver cancer or glioma, has high selectivity, has small toxicity to normal cell strains, and has better treatment effect compared with existing clinical drugs, such as cisplatin.
Owner:GUANGXI NORMAL UNIV OF SCI & TECH

8-hydroxyquinoline-based anticancer zinc(ii) complexes, methods for their synthesis and use

The application discloses an 8-hydroxyquinoline anticancer zinc (II) complex and a synthesis method and application thereof. The 8-hydroxyquinoline anticancer zinc (II) complex is synthesized by taking 5,7-diiodo-8-hydroxyquinoline, 5,7-dichloro-8-hydroxyquinoline, 5-chloro-7-iodo-8-hydroxyquinoline, 5,7-dibromo-8-hydroxyquinoline and 5-chloro-8-hydroxyquinoline as a first ligand and taking 4,4'-dimethoxy-2,2'-bipyridine, 4,4-di-tert-butyl-2,2-bipyridine, 5,5'-dimethyl-2,2-bipyridine, 2,2-bipyridine and 4,4'-dimethyl-2,2'-bipyridine as auxiliary ligands. The 8-hydroxyquinoline anticancer zinc (II) complex has good inhibiting effect on SK-OV-3CR cells of an ovarian cancer drug-resistant strain, is higher than that of cisplatin drugs, overcomes drug resistance of clinical drugs, has potential medicinal value and can be used for preparation of various antitumor drugs.
Owner:YULIN NORMAL UNIVERSITY

Pharmaceutical composition for preventing or treating cancer, comprising gossypol, phenformin, and anticancer agent

The present disclosure relates to a pharmaceutical composition comprising a combination of anticancer agents, capable of creating a synergistic effect when co-administer in the treatment of cancer, and more specifically, the present invention suggests anticancer agenst capable of creating a synergistic effect when co-administered with gossypol and phenformin. The anticancer agents selected as said anticancer agents in the present disclosure are sorafenib, vemurafenib, irinotecan, cisplatin, paclitaxel, and doxorubicin, and each of the aforementioned anticancer agent, when co-administered as a triple-drug combination with gossypol and phenformin can provide a significant synergistic effect in terms of the effect of suppressing the proliferation of cancer and killing cancer cell, compared to each mono-drug treatment group and a dual-drug treatment group of gossypol+phenformin.
Owner:NATIONAL CANCER CENTER(JP)

Preparation method and application of tridentate clamp type metal iridium complex

The invention discloses a preparation method and application of a tridentate metal iridium complex, the preparation method of the tridentate metal iridium complex comprises the following steps: step 1, substituted 1, 3-benzene diformate and 2-aminothiophenol are subjected to cyclization reaction to obtain a first intermediate; 2, reacting iridium trichloride hydrate with the first intermediate obtained in the step 1 to obtain a second intermediate; and step 3, reacting an LX ligand with the second intermediate obtained in the step 2, and then using silver trifluoromethanesulfonate to obtain a target product. The tridentate clamp type metal iridium complex disclosed by the invention is composed of a substituted-1, 3-bis (benzothiazolyl) benzene main ligand, a 2, 2-dipyridyl or phenanthroline NN ligand and balanced chloride ions. The complex is simple in synthesis method and has high cytotoxicity to cervical cancer cells, colon cancer cells and lung cancer cells, and the in-vitro cell toxicity of the complex is obviously superior to that of clinically applied anti-tumor drug cis-platinum, so that the complex has a good application prospect in the field of metal anti-cancer drugs.
Owner:HAINAN NORMAL UNIV

Application of senkyunolide I in preparation of medicine for preventing and treating organ injury and / or cytotoxicity induced by cis-platinum

The invention discloses application of senkyunolide I in preparation of a medicine for preventing and treating organ injury and / or cytotoxicity induced by cis-platinum, and belongs to the field of medicines, and the mass fraction of the senkyunolide I is greater than or equal to 90%; through a large number of tests, the inventor finds that senkyunolide I can reduce cytotoxicity induced by cis-platinum and improve cell activity; the kidney injury caused by cisplatin chemotherapy is relieved, and the renal tubule injury caused by cisplatin is relieved; the liver injury caused by cisplatin chemotherapy is relieved, the activity of glutamic oxalacetic transaminase and glutamic-pyruvic transaminase induced by cisplatin is reduced, and the degeneration and necrosis of liver cells caused by cisplatin are relieved; moreover, the senkyunolide I can be orally administered, so that the safety risk and adverse reaction caused by the conventional amifostine injection administration can be solved, and the senkyunolide I is expected to be developed into a cisplatin chemotherapy adjuvant drug which can be orally administered.
Owner:SICHUAN ACAD OF CHINESE MEDICINE SCI +1

A copper death-selective inducing nanoparticle targeting tumor mitochondria

The application belongs to the technical field of nanomedicine, tumor treatment and immunotherapy, and specifically provides a copper death selective induction nanoparticle targeting tumor mitochondria, which is prepared by the following preparation method: S1, TPY is specifically coupled with MHI through a condensation reaction to obtain MTPY; S2, MTPY is complexed with copper ions to obtain an MTPY-Cu complex; and S3, the MTPY-Cu complex is self-assembled with albumin to form an MTPY-Cu@Alb nanoparticle. The copper dose of the application is only 1 / 1000 of that of free Cu 2+ , and the equivalent immune regulation and killing effects can be achieved; the primary tumor and distant tumor foci can be inhibited, and lung metastasis can be reduced; and the application can induce immune memory and prevent recurrence; the application is combined with cisplatin to significantly enhance the therapeutic effect and reverse the induced immunosuppression; and the application has high biological safety, and has no obvious hepatorenal toxicity or hemolytic reaction.
Owner:THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV

Application of Phoximus in preparation of drugs for reversing gastric cancer drug resistance

The application discloses application of Ophisaurus apodus in preparation of a drug for reversing drug resistance of gastric cancer and belongs to the technical field of medicines. The application can reduce tumor volume and size, promote drug resistance cell apoptosis, and reverse the chemotherapeutic drug resistance of a nude mouse with gastric cancer by jointly using Ophisaurus apodus in different parts of the body and cisplatin, by down-regulating P-gp, MRP1 and Bcl-2 protein expression, and by up-regulating Bax protein expression. The effect of the tail + cisplatin group is the most significant.
Owner:NINGXIA MEDICAL UNIV

Application of combination of Molephantin and platinum chemotherapeutic drugs in preparation of drugs for treating nasopharynx cancer

The invention discloses an application of a combination of Molephantin and a platinum chemotherapeutic drug in preparation of a drug for treating nasopharynx cancer. The purpose of the invention is to show the pharmaceutical application of Molephantin in tumor growth resistance. In-vitro and in-vivo experiments are combined, and the result shows that the growth of nasopharyngeal carcinoma can be inhibited by combining the Molephantin with the cis-platinum and the oxaliplatin. The invention provides a new application of the combination of the Molephantin and the cis-platinum, and provides a new drug source for adjuvant therapy of cancers.
Owner:THE FIRST AFFILIATED HOSPITAL OF JINAN UNIV